Shuttle Pharmaceuticals Holdings, Inc. (SHPH)
$0.00+$0.00 (+0.00%) TodayExtended Hours
Shuttle Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company leveraging its proprietary technology to develop novel therapies designed to cure cancers. The company has one operating segment with a focus on the development of novel drug therapies, including cancer therapies, extending new applications of radiation therapy, and other drug development, including through the use of the Molecule.ai platform by the company as well as licensing the right to use Molecuile.ai to others. The company's goal is to extend the benefits of cancer treatments with surgery, radiation therapy, chemotherapy and immunotherapy. Radiation therapy (RT) is one of the effective modalities for treating cancers. Its pipeline includes: Ropidoxuridine, HDAC Inhibitors, PSMA-B, and PC-Rad Test.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market purchase | 6 | 53,398 | $182K |
| Open-market sale | 5 | 121,282 | $505K |
12 Form 4 filings on record, the earliest from Oct 9, 2024, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| HRT FINANCIAL LP - 10% Owner | Open-market sale | Common Stock | 1,033 | $4.67 | $5K | |
| HRT FINANCIAL LP - 10% Owner | Open-market sale | Common Stock | 82,116 | $4.48 | $368K | |
| HRT FINANCIAL LP - 10% Owner | Open-market purchase | Common Stock | 8,266 | $3.38 | $28K | |
| HRT FINANCIAL LP - 10% Owner | Open-market purchase | Common Stock | 731 | $3.11 | $2K | |
| HRT FINANCIAL LP - 10% Owner | Open-market sale | Common Stock | 10,580 | $3.33 | $35K | |
| HRT FINANCIAL LP - 10% Owner | Open-market sale | Common Stock | 18,531 | $3.52 | $65K | |
| HRT FINANCIAL LP - 10% Owner | Open-market purchase | Common Stock | 7,851 | $3.54 | $28K | |
| HRT FINANCIAL LP - 10% Owner | Open-market sale | Common Stock | 9,022 | $3.51 | $32K | |
| HRT FINANCIAL LP - 10% Owner | Open-market purchase | Common Stock | 3,959 | $3.30 | $13K | |
| HRT FINANCIAL LP - 10% Owner | Open-market purchase | Common Stock | 25,836 | $3.44 | $89K | |
| HRT FINANCIAL LP - 10% Owner | Open-market purchase | Common Stock | 6,755 | $3.23 | $22K | |
| Steven M. Richards - Director | Grant or award | Restricted Stock Unit | 29,240 | $0.00 | - | |
| Joseph Tung - Director | Grant or award | Restricted Stock Unit | 29,240 | $0.00 | - | |
| Timothy J. Lorber - Officer | Grant or award | Restricted Stock Unit | 29,240 | $0.00 | - | |
| Timothy J. Lorber - Officer | Grant or award | Restricted Stock Unit | 24,854 | $0.00 | - | |
| Oleh Nabyt - Director | Grant or award | Restricted Stock Unit | 29,240 | $0.00 | - | |
| George Scorsis - Director | Grant or award | Restricted Stock Unit | 29,240 | $0.00 | - | |
| Mira Jung - Officer | Grant or award | CLASS A COMMON STOCK | 598 | $22,560.00 | $7K |
Shuttle Pharmaceuticals Holdings, Inc. (SHPH) had 6 insider filings in the last 90 days, with the most recent on 2026-07-15. The full record for SHPH runs to 12 Form 4 filings, the earliest from 2024-10-09. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
6 insider purchases of SHPH were filed in the last 90 days, totaling $182K.
5 insider sales of SHPH were filed in the last 90 days, totaling $505K.
This page tracks SHPH Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add SHPH to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
